This is the authors' abstract. We don't add key points for this paper.
A first-in-human, stem-cell-based trial for Parkinson's disease raises specific ethical issues. We analyze three challenges: participant selection, informed consent, and sham surgery. Phase I–II studies should recruit patients under 70 years of age with levodopa-responsive main features, free of nonmotor, levodopa-resistant symptoms and of complications of long-term dopamine replacement therapy. Recruitment should avoid the first months following diagnosis and exclude candidates for deep brain stimulation. A shorter overall life expectancy would be preferable to minimize cumulative risks of tumorigenesis. Participants should understand that research participation would not be a “last chance” scenario. Sham surgery would be unjustified as a placebo control in Phase I–II but may be required as a standardized negative, requiring intracranial injection, in Phase III trials. Potential participants fulfilling these conditions exist. Provided special precautions are taken with the design of first-in-human studies, such trials can be conducted in an ethically justified manner.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hurst et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: